As the Bundibugyo Ebola virus outbreak continues to spread in the Democratic Republic of the Congo, the first of four vaccine candidates has entered clinical trials. Katharine Lang reports on what is known about them and the UK’s key role in the trials
The ongoing 2026 outbreak of Bundibugyo virus (BDBV) in the Democratic Republic of the Congo and Uganda is the largest so far on record. Despite experience from previous Ebolavirus outbreaks, the current lack of vaccines against BDBV underscores a recurring failure in proactive preparedness. Here, we explore the most p...
An outbreak of Ebola disease caused by Bundibugyo virus (BDBV) has been ongoing since April 2026, primarily in the Democratic Republic of the Congo. We estimated the initial reproduction number of BDBV at 1.85 (95% CrI: 1.09, 3.25), underscoring the urgent need for timely implementation of control measures to prevent w...
This Perspective describes the Vaccine Integrity Project, established in 2025 in response to concerns about the stability and integrity of US vaccine policy due to disruptions to the work of the Advisory Committee on Immunization Practices; outlines the process for the 2026-2027 evidence review; and summarizes key fi...
[This corrects the article DOI: 10.3389/frhs.2026.1648814.].
Ebola virus disease and Marburg virus disease are severe, highly lethal infections caused by filoviruses, characterized by rapid transmission, complex clinical management, and major socio-economic impact. A narrative review of recent outbreaks between 2021 and 2025 underscores persistent systemic gaps that compromise e...
The 2026 Ebola outbreak caused by Bundibugyo ebolavirus in the Democratic Republic of the Congo and Uganda exposes a persistent structural flaw in global health security: preparedness remains overwhelmingly reactive and pathogen-specific. Despite the $518 million Africa CDC-WHO joint continental plan, no licensed BDBV...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
